1. Al Ismail SAD, Whittaker JA (1979) Systolic time interval as index of schedule-dependent doxorubicin cardiotoxicity in patients with acute myelogenous leukemia. Br Med J 1:1392–1395
2. Bonadonna G, Beretta G, Tancini G, Brambilla C, Bajetta E, De Palo GM, De Lena M, Fossati Bellani F, Gasparini M, Valagussa P, Veronesi U Adriamycin (NSC-123127) studies at the Istituto Nazionale Tumori, Milan. Cancer Chemother Rep (part 3) 6:231-245
3. Bonfante V, Bonadonna G, Villani F, Di Fronzo G, Martini A, Casazza AM (1979) Preliminary phase I study of 4’-epi-adriamycin. Cancer Treat Rep 63:915–918
4. Blum RH, Carter SK (1974) Adriamycin, a new anticancer drug with significant clinical activity. Ann Intern Med 80:249–259
5. Casazza AM, Di Marco A, Bertazzoli C, Formelli F, Giuiliani F, Pratesi G (1978) Antitumor activity, toxicity and pharmacological properties of 4’-epi-adriamycin. Curr Chemother 2:1257–1260